319.43

0.31% -0.99

After Hours: 319.43

Ligand Pharmaceuticals Inc (LGND)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split Dividend History

Ligand Pharmaceuticals Inc stock is traded at $319.43, with a volume of 316.45K. It is down -0.31% in the last 24 hours and up +34.78% over the past month. Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

Previous Close:

$320.42

Open:

$317.97

24h Volume:

316.45K

Relative Volume:

0.99

Market Cap:

$6.40B

Revenue:

$274.48M

Net Income/Loss:

$153.56M

P/E Ratio:

43.31

EPS:

7.3755

Net Cash Flow:

$114.06M

1W Performance:

+1.06%

1M Performance:

+34.78%

6M Performance:

+59.75%

1Y Performance:

+180.79%

1-Day Range:

$312.74

$323.30

1-Week Range:

$305.31

$323.30

52-Week Range:

$114.00

$323.30

Ligand Pharmaceuticals Inc Stock (LGND) Company Profile

Name

Ligand Pharmaceuticals Inc

Sector

Healthcare (1094)

Industry

Biotechnology (615)

Phone

858-550-7500

Address

3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA

Employee

Twitter

@Ligand_LGND

Next Earnings Date

2026-08-06

Latest SEC Filings

LGND's Discussions on Twitter

Compare LGND vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LGND Ligand Pharmaceuticals Inc	319.43	6.42B	274.48M	153.56M	114.06M	7.3755
VRTX Vertex Pharmaceuticals Inc	522.25	134.41B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	676.23	68.13B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	919.93	57.01B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	321.50	41.79B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	190.46	40.39B	742.00K	-1.37B	-1.07B	-7.0731

Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-11-26	Initiated	BofA Securities	Buy
Dec-09-25	Initiated	Citigroup	Buy
Apr-10-25	Initiated	Stifel	Buy
Oct-03-24	Initiated	Oppenheimer	Outperform
Jul-30-24	Initiated	RBC Capital Mkts	Outperform
Apr-14-21	Resumed	Stephens	Overweight
Feb-04-21	Reiterated	H.C. Wainwright	Buy
Oct-06-20	Initiated	Barclays	Overweight
Mar-24-20	Downgrade	Argus	Buy → Hold
Mar-10-20	Initiated	Guggenheim	Neutral
Feb-06-20	Initiated	The Benchmark Company	Buy
Sep-19-19	Upgrade	Barclays	Equal Weight → Overweight
Jun-11-19	Initiated	Barclays	Equal Weight
May-03-19	Reiterated	H.C. Wainwright	Buy
Mar-06-19	Reiterated	H.C. Wainwright	Buy
Oct-29-18	Upgrade	ROTH Capital	Neutral → Buy
Oct-02-18	Reiterated	H.C. Wainwright	Buy
Sep-11-18	Reiterated	Argus	Buy
Aug-17-18	Initiated	Goldman	Neutral
Aug-08-18	Downgrade	ROTH Capital	Buy → Neutral
Jun-21-18	Initiated	Argus	Buy
Dec-27-17	Reiterated	H.C. Wainwright	Buy
Sep-05-17	Resumed	H.C. Wainwright	Buy
Oct-05-16	Reiterated	H.C. Wainwright	Buy
Aug-05-16	Downgrade	Deutsche Bank	Hold → Sell
Mar-11-16	Initiated	Sidoti	Buy
Mar-03-16	Initiated	H.C. Wainwright	Buy

View All

Ligand Pharmaceuticals Inc Stock (LGND) Latest News

Jul 06, 2026

Form 4 Ligand Pharmaceuticals Incorporated For: 6 July By Investing.com - Investing.com Canada

Jul 06, 2026

Ligand Pharmaceuticals CLO Andrew Reardon sells $1.56m in shares By Investing.com - Investing.com Canada

Jul 06, 2026

[Form 4] LIGAND PHARMACEUTICALS INC Insider Trading Activity - Stock Titan

Jul 06, 2026

Ligand Pharmaceuticals (LGND) CFO adds 17 shares through stock purchase plan - Stock Titan

Jul 06, 2026

LGND CEO Todd Davis acquires stock through employee plan in Form 4 filing - Stock Titan

Jul 06, 2026

Ligand Pharmaceuticals stock hits all-time high at 321.33 USD - Investing.com

Jul 06, 2026

CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool

Jul 06, 2026

Jul 03, 2026

Ligand Pharmaceuticals explores licensing-driven growth as investors assess its royalty model - AD HOC NEWS

Jul 03, 2026

Ligand Pharmaceuticals Is Buying Xoma for Nearly $740 Million -- WSJ - Moomoo

Jul 03, 2026

Jul 02, 2026

Enterprise value to EBITDA forward of Ligand Pharmaceuticals Incorporated – OTC:LGNXZ - TradingView

Jul 02, 2026

TVTX, LGND Stocks In Spotlight Ahead Of Monday’s FDA Call On Kidney Drug Filspari - Stocktwits

Jul 02, 2026

Jul 01, 2026

LGND: 10,000-share Section 144 notice; prior 10b5-1 sales by Reardon (LGND) - Stock Titan

Jul 01, 2026

Enterprise value to revenue forward of Ligand Pharmaceuticals Incorporated – OTC:LGNXZ - TradingView

Jul 01, 2026

Jun 30, 2026

Ligand Pharma: Expect Bright And Exciting Future For This Growing Royalty Aggregator - Seeking Alpha

Jun 30, 2026

Price to sales forward of Ligand Pharmaceuticals Incorporated – OTC:LGNXZ - TradingView

Jun 30, 2026

Ligand Pharmaceuticals reaches new 52-week high as insiders trim holdings - AD HOC NEWS

Jun 30, 2026

Zerion Pharma completes royalty financing and equity investment transaction with Ligand to advance the Dispersome® technology - marketscreener.com

Jun 30, 2026

Enterprise value to revenue forward of Ligand Pharmaceuticals Incorporated – OTC:LGNDZ - TradingView

Jun 30, 2026

Jun 29, 2026

Enterprise value to EBITDA forward of Ligand Pharmaceuticals Incorporated – NASDAQ:LGND - TradingView

Jun 29, 2026

Price to sales forward of Ligand Pharmaceuticals Incorporated – OTC:LGNDZ - TradingView

Jun 29, 2026

Enterprise value to EBITDA forward of Ligand Pharmaceuticals Incorporated – OTC:LGNDZ - TradingView

Jun 29, 2026

Enterprise value to EBIT forward of Ligand Pharmaceuticals Incorporated – OTC:LGNDZ - TradingView

Jun 29, 2026

Price to book forward of Ligand Pharmaceuticals Incorporated – OTC:LGNDZ - TradingView

Jun 29, 2026

Price to earnings forward of Ligand Pharmaceuticals Incorporated – OTC:LGNDZ - TradingView

Jun 29, 2026

Enterprise value to EBIT forward of Ligand Pharmaceuticals Incorporated – NASDAQ:LGND - TradingView

Jun 29, 2026

Ligand Pharmaceuticals Incorporated(NasdaqGM:LGND) dropped from Russell 2000 Value-Defensive Index - marketscreener.com

Jun 29, 2026

Ligand Pharmaceuticals Incorporated(NasdaqGM:LGND) dropped from Russell 2000 Value Benchmark - marketscreener.com

Jun 29, 2026

Enterprise value to EBIT forward of Ligand Pharmaceuticals Incorporated – BX:LGDN - TradingView

Jun 29, 2026

Enterprise value to revenue forward of Ligand Pharmaceuticals Incorporated – NASDAQ:LGND - TradingView

Jun 29, 2026

Jun 28, 2026

Price to earnings forward of Ligand Pharmaceuticals Incorporated – NASDAQ:LGND - TradingView

Jun 28, 2026

Price to earnings forward of Ligand Pharmaceuticals Incorporated – BX:LGDN - TradingView

Jun 28, 2026

Price to book forward of Ligand Pharmaceuticals Incorporated – BX:LGDN - TradingView

Jun 28, 2026

Ligand Pharmaceuticals Incorporated(NasdaqGM:LGND) dropped from Russell 3000 Value Benchmark - marketscreener.com

Jun 28, 2026

Price to sales forward of Ligand Pharmaceuticals Incorporated – BX:LGDN - TradingView

Jun 28, 2026

Ligand Pharmaceuticals Incorporated(NasdaqGM:LGND) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com

Jun 28, 2026

Jun 27, 2026

XOMA Royalty (XOMA) Stock Fair Value Falls After Ligand Agrees Cash Acquisition - Yahoo Finance

Jun 27, 2026

Ligand Pharmaceuticals Incorporated Actuals & Estimates (NASDAQ:LGND) - TradingView

Jun 27, 2026

Jun 26, 2026

Ligand completes $700m convertible notes offering By Investing.com - Investing.com Australia

Jun 26, 2026

LGND Forecast — Price Target — Prediction for 2027 - TradingView

Jun 26, 2026